Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

BACKGROUND: The addition of Rituximab (R) to standard chemotherapy (C) has been reported to improve the end of treatment outcome in patients affected by CD-20 positive malignant lymphomas (CD20+ ML). Nevertheless, given the profound and prolonged immunosuppression produced by R there are concerns th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanini, Simone, Molloy, Aoife C, Fine, Paul E, Prentice, Archibald G, Ippolito, Giuseppe, Kibbler, Christopher C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094236/
https://www.ncbi.nlm.nih.gov/pubmed/21481281
http://dx.doi.org/10.1186/1741-7015-9-36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094236/
https://www.ncbi.nlm.nih.gov/pubmed/21481281
http://dx.doi.org/10.1186/1741-7015-9-36

Ejemplares similares